Europe Pharmacogenomics Technology Market Size & Outlook

The pharmacogenomics technology market in Europe is expected to reach a projected revenue of US$ 3,398.4 million by 2030. A compound annual growth rate of 8% is expected of Europe pharmacogenomics technology market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,987.8
Forecast, 2030 (US$M)
$3,398.4
CAGR, 2024 - 2030
8%
Report Coverage
Europe

Europe pharmacogenomics technology market, 2018-2030 (US$M)

Europe

Europe pharmacogenomics technology market highlights

  • The Europe pharmacogenomics technology market generated a revenue of USD 1,987.8 million in 2023.
  • The market is expected to grow at a CAGR of 8% from 2024 to 2030.
  • In terms of segment, oncology was the largest revenue generating therapeutics area in 2023.
  • Oncology is the most lucrative therapeutics area segment registering the fastest growth during the forecast period.


Europe data book summary

Market revenue in 2023USD 1,987.8 million
Market revenue in 2030USD 3,398.4 million
Growth rate8% (CAGR from 2023 to 2030)
Largest segmentOncology
Fastest growing segmentOncology
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationOncology
Key market players worldwideQiagen NV, GE HealthCare Technologies Inc Common Stock, Agilent Technologies Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Pfizer Inc, Leica Biosystems, Foundation Medicine


Other key industry trends

  • In terms of revenue, Europe region accounted for 28.8% of the global pharmacogenomics technology market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 3,506.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Pharmacogenomics Technology Market Scope

Pharmacogenomics technology market segmentation & scope
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Infectious Diseases
Others
Technology
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Countries
U.S.
Canada
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Japan
China
India
Australia
South Korea
Thailand
Mexico
Brazil
South Africa
Saudi Arabia
UK
Argentina
UAE
Kuwait

Pharmacogenomics Technology Market Companies

Name Profile # Employees HQ Website

Europe pharmacogenomics technology market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmacogenomics technology market will help companies and investors design strategic landscapes.


Oncology was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe pharmacogenomics technology market based on oncology covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Europe pharmacogenomics technology market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe pharmacogenomics technology market databook

  • Our clientele includes a mix of pharmacogenomics technology market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe pharmacogenomics technology market , including forecasts for subscribers. This continent databook contains high-level insights into Europe pharmacogenomics technology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe pharmacogenomics technology market

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more